Docasap and healthsparq collaborate to help payers improve the member experience

Medcity | April 28, 2019

Through their partnership, the companies will integrate docasap's real-time online scheduling with healthsparq's provider and cost search capabilities in one platform.

Spotlight

People can choose from a subcutaneous ICD (S-ICD) and a transvenous ICD?


Other News
FUTURE OF HEALTHCARE

Virta Health Highlights Lasting, Transformative Health Improvements In 5-Year Diabetes Reversal Study

Virta Health | June 07, 2022

Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions. Presenting four unique abstracts, Virta highlighted myriad, lasting health improvements for people with type 2 diabetes and prediabetes, including blood sugar control, clinically-significant weight loss, reduced inflammation, and improvements in other markers of cardiometabolic health. These transformative health outcomes coincided with medication reduction or elimination for many trial patients, including Jane Ann Dimitt. For over two decades, Jane Ann was prescribed increasing levels of medications as her blood sugar and weight continued to climb. By the time she joined Virta in 2015, her A1c had reached 11.4%; the next step was insulin. Through Virta’s treatment, Jane Ann lowered her blood sugar to 5.5% (below even the prediabetes threshold) and lost over 50 pounds, while drastically reducing her reliance on medications. She also saw improved mobility, decreased inflammation and neuropathy, and now has the energy to play with her grandchildren—all without needing the insulin doctors said was imminent. The outcomes of Jane Ann and Virta’s other trial patients contradict the belief that progression of diabetes—and a lifetime of increasing medications—is inevitable. One-fifth of Virta patients completing five years of treatment saw full remission. One-third of patients achieved A1c below 6.5% without any diabetes medications, or only requiring Metformin. Notably, inflammatory markers, triglycerides, and HDL cholesterol all improved significantly. These outcomes, in conjunction with previous research demonstrating improvements in cardiovascular disease risk factors, depression symptoms, sleep, and knee pain, establish the promise of Virta’s approach to impact a wide range of conditions amid America’s metabolic disease epidemic. In the U.S., costs are rising as patient outcomes continue to worsen, including surges in amputations, hyperglycemic events, and diabetes-related deaths during the COVID-19 pandemic. Meanwhile, getting patients to stick with an intervention remains a significant challenge in diabetes therapy. Rates of medication adherence—that is, whether patients take their medications as prescribed—fall as low as 34% over the first three years for those starting insulin. For the National Diabetes Prevention Program, considered the gold standard in lifestyle interventions, only 13% of patients were retained at one year. In contrast, in Virta’s trial nearly 50% of participants with type 2 diabetes were retained at five years. Of those who continued past year two, 72% remained for an additional three years to year five. For Kim Shepherd, who lost 55 pounds, eliminated 10 different medications, reversed her diabetes, and even saw her GERD (acid reflux) and plantar fasciitis disappear, the reasons to stick with the treatment are clear. “Diabetes runs in my family, and I know that this disease can rob you of your whole life; it can take your eyes, your feet, and your kidneys. I have 4 kids and 9 grandkids to keep up with. I’ve learned to love hiking and biking. Nothing is worth losing all of that and going back to how I was before.” Additional key outcomes demonstrating the success of Virta’s approach at five years include Sustained blood sugar control. Virta patients experienced persistent improvements in blood sugar on average, while requiring significantly fewer medications. Medication deprescription. Half of patients prescribed insulin at the start of the trial no longer needed it at five years. Across all diabetes drugs, prescriptions were reduced by nearly 50%. Weight loss. Average weight among Virta participants decreased by 7.6%, exceeding the 5% benchmark for clinically significant weight loss by more than 50%. Broad improvement in cardiometabolic health. In addition to improvements in triglycerides, HDL cholesterol, and markers of inflammation, patients even showed encouraging signs in reversing the progression of chronic kidney disease. “Virta’s patients are helping redefine what long-term success can look like in type 2 diabetes care. The patient outcomes set a new standard for real-world applications of diabetes treatment." Dr. Alan Moses, former Senior Vice President and Global Chief Medical Officer of Novo Nordisk, and Virta advisor Trial participants with prediabetes also saw meaningful improvements, with progression rates far below what has been demonstrated in other studies. Further, Virta patients sustained 6% weight loss over five years, exceeding the clinically-significant benchmark for diabetes prevention and far surpassing the 2% weight loss observed in the NIH Diabetes Prevention Program lifestyle intervention. The study is also notable for its longevity. Five-year published results are extremely rare in digital health, where most studies follow populations for no more than a year, and usually significantly less. For many Virta patients, the five-year clinical trial has facilitated a lasting lifestyle change, improving not only traditional markers of health but overall mood, quality of life, and outlook on the future. Says patient Denise Lamb, who has maintained diabetes reversal alongside a nearly 70 pound weight loss, “My journey has been phenomenal. The Virta program has not only helped me achieve healthy blood glucose, but also attain a far better weight, normal blood pressure, and better understanding of my body. Virta’s lifestyle changed my lifestyle!” About Virta Health Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches manage disease progression through increased medication use and infrequent doctor visits. Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts. In clinical studies, 94% of patients reduce or eliminate insulin use, and weight-loss exceeds FDA benchmarks by nearly 150%. Virta works with the largest health plans, employers, and government organizations and puts 100% of its fees at risk based on clinical and financial outcomes.

Read More

FUTURE OF HEALTHCARE

Ascensus Closes Newport Merger Agreement

Ascensus | April 11, 2022

Ascensus—whose technology and expertise help millions of people save for retirement, education, and healthcare—and Newport, the Walnut Creek, California-based retirement services provider—announced today that the two companies have closed their previously announced merger, the first step in their journey together as a combined organization. The union combines the capabilities and talents of two market leaders in tax-advantaged savings and related services, serving more than 15 million savers and overseeing more than $745 billion in assets under administration as of December 31, 2021. Together, the unified company employs more than 5,400 employees across the U.S. David Musto, president and chief executive officer of Ascensus, will serve as CEO of the combined company. Laura Ramanis, who has served as interim CEO of Newport since the announcement of the transaction last fall, and Kurt Laning, executive vice president of Newport Non-Qualified and Insurance Solutions, will join the Ascensus executive leadership team, reporting to Musto. "With today's announcement, Ascensus and Newport have taken an important step in our journey towards a stronger, unified company. Clients across our lines of business will benefit from our expanded capabilities—accelerated investments in technology, data analytics, and user experiences—and broadened expertise. And both Ascensus and Newport associates can look forward to new opportunities for personal growth and enhanced career development." Musto "Ascensus and Newport share a passion for helping people save for their futures and supporting the growth and success of our partners," said Ramanis. "We look forward to continuing that mission as a combined company." With industry-leading qualified and non-qualified retirement plan services, corporate and bank-owned life insurance (COLI and BOLI) practices, fiduciary and trust solutions, and other total rewards capabilities, Newport expands the services and expertise Ascensus provides to its clients and advisor partners. Newport's clients will benefit from greater access to unique tax-advantaged savings solutions across retirement, education, and health provided by Ascensus. The combined company's investments in technology, digital capabilities, and analytics will deliver enhanced value to clients, expand client relationships, and create even better outcomes for savers. Both the Ascensus and Newport brands remain in use at closing, with the Ascensus brand representing the unified company. "Our goal over the next several months is the successful unification of our company—built on the principle of 'best of the best' and our shared cultural attributes, and executed with the interests, quality, and stability of our client relationships foremost in mind," added Musto. "As a unified organization, Ascensus and Newport share a strong commitment to serving our clients and offering more—across the tax-advantaged retirement, education, and health savings expertise for which Ascensus is known, and capitalizing on Newport's well-established qualified and non-qualified retirement services, and fiduciary and COLI/BOLI capabilities as well." Evercore acted as exclusive financial advisor to Newport in connection with the transaction. Goldman Sachs Bank USA, SPC Financing Company LLC, and KKR Capital Markets LLC led the financing consortium. Simpson Thacher & Bartlett LLP acted as transactional counsel to Ascensus and Kirkland & Ellis LLP acted as financing counsel to Ascensus. Morgan Lewis & Bockius LLP acted as legal counsel to Newport. About Ascensus Ascensus helps millions of people save for what matters—retirement, education, and healthcare. Through co-branded, private-labeled, and other governmental partnerships, our technology, market insights, and business knowledge enhance the growth and success of our partners, their clients, and savers. Ascensus is a leading recordkeeping services provider, third-party administrator, and government savings facilitator in the United States. About Newport Headquartered in Walnut Creek, California, Newport is a leading retirement services provider that helps employers—and the advisors who serve them—prepare employees for a more financially secure retirement. The company has more than $150 billion in retirement assets under administration and more than $300 billion in corporate retirement and insurance assets. Newport maintains investment objectivity, fee transparency and a commitment to flexible, responsive service. Staffed by an exceptional team of nearly 1,500 retirement, insurance, and consulting professionals, the company provides retirement solutions tailored to the needs of employers of every size, from small businesses to the Fortune 1000.

Read More

FUTURE OF HEALTHCARE

SpinaFX Medical to Exhibit at Society of Interventional Radiology Annual Scientific Meeting

Spinafx medical inc | June 13, 2022

Minimally invasive image-guided therapy company, SpinaFX Medical Inc. announced it will exhibit at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting inBoston, MA,June 11-16, at booth 414. Dr. Alexis Kelekis, medical advisor to SpinaFX, will present the results of a research study on which he was the lead author, recently published inThe Spine Journal, on the effectiveness of intradiscal oxygen-ozone treatment compared to microdiscectomy for contained lumbar disc herniation with radiculopathy. This study has been recognized by SIR as one of the 2022Abstracts of the Year. "We are excited to meet with some of the world's leading interventional radiologists to discuss innovations in minimally invasive, image-guided care and share our recent progress and momentum at SpinaFX. We look forward to Dr. Kelekis' presentation and celebrate the study's findings, which have the potential to benefit both patients and providers by addressing a significant gap in the continuum of care for the millions suffering from back pain." Jeff Cambra, SpinaFX CEO "I am thrilled that Dr. Kelekis will share the findings of our skilled research team at SIR's Annual Scientific Meeting," said Dr.Kieran Murphy, SpinaFX Chief Medical Officer and co-author of the recognized study. "The technology used in this randomized control trial holds great promise for patients struggling with contained herniated lumbar disc pain and it is an honor to have this research recognized by such a prestigious and well-respected organization." Dr. Alexis Kelekis willpresentthe results of his study onWednesday, June 15, at10:40 a.m.during Closing Plenary. As an exhibitor during the meeting onJune 11-16, SpinaFX will offer attendees the opportunity to discuss the study results and their implications with Drs. Kelekis and Murphy, learn more about SpinaFX and its goal to help develop minimally invasive, image-guided treatment options, and provide input on developing technology with the potential to redefine the treatment of contained herniated discs. Visit SIR'swebsiteto learn more about the Annual Scientific Meeting. About SpinaFX Headquartered inOntario, Canada, SpinaFX is a treatment solution and technology company bringing innovative, minimally invasive image-guided treatments to patients with back pain due to contained herniated discs.

Read More

HEALTH TECHNOLOGY

The GIANT Health Event 2021. Early bird tickets on sale now

GIANT Health | October 13, 2021

Europe's greatest festival of Health Tech Innovation | 30th Nov - 1st Dec 2021 Join us at GIANT this year and immerse yourself in Europe's greatest festival of healthcare innovation. Find inspiration from global leading innovators, and discover the advances in technology that are revolutionizing healthcare provision. GIANT 2021 is set to be our biggest event yet so don't miss out. GIANT Health event is an invaluable, cost-effective global hybrid event. Combining both a real-world physical trade show and multiple conferences in central London, as well as a sophisticated and engaging virtual event based on GIANT Health’s proprietary Virtual Event Platform. Learn more about Digital Therapeutics.Would you like to network with 1000s and 1000s of Europe's leading healthcare and technology innovators, hospital leaders, health-sector investors, and entrepreneurs?Over 400 speakers will convene in 15+ conference at the massive GIANT Health Event, 30 November - 1 December, 2021. Come join us in person or remotely.Early Bird tickets are now available. CLAIM YOUR TICKET HERE A special promotional code which allows to save up to 25% on top is available for our subscribers: MEDIA25 See you there! Media contact: GIANT Health Events Ltd Olga Nosova +44 20 8144 9779 Olga@GIANT.health

Read More